According to a report ," Spinal Muscular Atrophy (SMA) Treatment Market Size, Share & Trends Analysis Report By Route of Administration (Oral, Intrathecal), By Treatment (Gene Therapy, Drug), By Disease Type, And Segment Forecasts, 2018 - 2025" published by Grand View Research, Inc., The global spinal muscular atrophy (SMA) treatment market size is expected to reach USD 3.9 billion by 2025. It is estimated to register a CAGR of 12.9% during the forecast period. Due to the rare nature and complexity of these diseases, scientific knowledge pertaining to them is scarce. However, there are various initiatives undertaken to increase awareness regarding rare diseases and to support SMA communities. This is anticipated to boost the market development over the coming years.
Key Takeaways from the report:
-
The global spinal muscular atrophy treatment market is projected to expand at a CAGR of 12.9% over the forecast period
-
Based on disease type, type 1 accounted for the largest revenue share owing to rising incidence of type 1 SMA
-
By treatment, the drug segment accounted for the largest revenue share in 2017
-
North America will retain its lead as the largest regional market; however Asia Pacific is anticipated to register the fastest CAGR over the forecast period
-
Themarket is presently led by Biogen Inc. Biogen’s Spinraza is the only approved commercialized treatment for SMA, owing to which market is not competitive. However, this trend is expected to change after the commercialization of other treatment therapies post 2020
Browse More Reports in Pharmaceuticals Industry:
- Pharmaceutical Cartridges Market : Rising awareness regarding the benefits of using pharmaceutical cartridges in the packaging industry is propelling the market demand.
- Migraine Drugs Market: The market is largely driven by factors such as rise in disease prevalence, development of novel therapies, lifestyle changes, and hormonal medications
Various SMA communities and companies have collaborated for developing disease treatment therapy. For example, RG7916, which is an investigational therapy being developed by Roche in collaboration with SMA Foundation and PTC Therapeutics. Thus, heavy investments in R&D by major companies are also projected to contribute toward the growth of this market. CureSMA, SMA Foundation, and SMA Europe are some of the organizations actively supporting R&D pertaining to SMA.
CureSMA provided funding to a research project to Biogen and Ionis Pharmaceuticals, Inc. for developing Spinraza, which received U.S. FDA approval in 2016. This organization has invested nearly USD 70 million in the research pertaining to SMA, which also included a planned investment of USD 5 million in the coming years.
Grand View Research has segmented the global spinal muscular atrophy treatment market on the basis of disease type, treatment, route of administration, and region:
SMA Treatment Disease Type Outlook (Revenue, USD Million, 2015 - 2025)
-
Type 1
-
Type 2
-
Type 3
-
Type 4
SMA Treatment Outlook (Revenue, USD Million, 2015 - 2025)
-
Gene Therapy
-
Drug
-
Spinraza
-
RG6083 (Olesoxime)
-
RG7916
-
SMA Treatment Route of Administration Outlook (Revenue, USD Million, 2015 - 2025)
-
Oral
-
Intrathecal
SMA Treatment Regional Outlook (Revenue, USD Million, 2015 - 2025)
-
North America
-
U.S.
-
Canada
-
-
Europe
-
U.K.
-
Germany
-
-
Asia Pacific
-
Japan
-
China
-
-
Latin America
-
Mexico
-
Brazil
-
-
Middle East & Africa
-
South Africa
Explore the BI enabled intuitive market research database, Navigate with Grand View Compass, by Grand View Research, Inc.
About Grand View Research
Grand View Research provides syndicated as well as customized research reports and consulting services on 46 industries across 25 major countries worldwide. This U.S.-based market research and consulting company is registered in California and headquartered in San Francisco. Comprising over 425 analysts and consultants, the company adds 1200+ market research reports to its extensive database each year. Supported by an interactive market intelligence platform, the team at Grand View Research guides Fortune 500 companies and prominent academic institutes in comprehending the global and regional business environment and carefully identifying future opportunities.
For more information: www.grandviewresearch.com/
Media Contact
Company Name: Grand View Research, Inc.
Contact Person: Sherry James, Corporate Sales Specialist - U.S.A.
Email:Send Email
Phone: 1-415-349-0058, Toll Free: 1-888-202-9519
Address:201, Spear Street, 1100
City: San Francisco
State: California
Country: Switzerland
Website: www.grandviewresearch.com/industry-analysis/spinal-muscular-atrophy-sma-treatment-market
